

Obesity

**LI2022-0310**

Score: 65,0

**Effectiveness of using Semaglutide combined with GluCare Health Hybrid Care Model for weight loss management**

*Y. SAID<sup>1</sup>, M. Caccelli<sup>1</sup>, B. van Wagensveld<sup>2</sup>, S. Aleabova<sup>3</sup>, C. Palsky<sup>4</sup>, V. Munirathinam<sup>5</sup>, A. Hashemi<sup>4</sup>, I. Almarzooqi<sup>4</sup>*

*<sup>1</sup>Glucare Integrated Diabetes Center, Diabetes, Dubai, United Arab Emirates*

*<sup>2</sup>Glucare Integrated Diabetes Center, Bariatric Management, Dubai, United Arab Emirates*

*<sup>3</sup>Glucare Integrated Diabetes Center, Nurse manager, Dubai, United Arab Emirates*

*<sup>4</sup>Glucare Integrated Diabetes Center, Management, Dubai, United Arab Emirates*

*<sup>5</sup>Glucare Integrated Diabetes Center, Statistic Analyze, Dubai, United Arab Emirates*

**Background**

GluCare Health is a vertically integrated, hyper-personalized diabetes platform. Remote Continuous Data Monitoring (RCDM) begins post visit tracking digital biomarkers that are analyzed by Machine learning algorithms, allowing the care team to action data driven insights.

**Aim**

GluCare previously demonstrated significant improvements for diabetes management (1.2). This current study aims to demonstrate an important improvement in weight loss for T2DM and obese patients through lifestyle modification and therapeutic treatment with medication adjustment.

**Method**

Eighteen participants using injectable Semaglutide were enrolled. Additional non-GLP1 medications (N=10). Average BMI over 30 and

average HbA1c  $\geq 6.5$  was recorded within one month from consultation. Compliance criteria included engagement, weight, and glucose monitoring.

**Results**

The GluCare Health model (regardless of additional medications) led to improvements in weight loss of 7.4 KG TWL. These results showed 40% greater weight loss in 60% less time in comparison to previous studies (3). Secondary outcome showed HbA1c reduction of 1.02.

**Conclusion**

Our results suggest that GluCare' model can increase engagement and adherence, reduce HbA1c and has the potential to accelerate weight loss in

a shorter period in comparison with episodic care.

a shorter period in comparison with episodic care.

## **References**

1) Implementation of Remote Continuous Data Monitoring within a Clinical Setting for the Management of Type 2 Diabetes Mellitus, Milena Caccelli\* , Yousef Said, Joena Mojado, Carolyn Palsky, Ali Hashemi & Ihsan Almarzooqi, ADA 82nd Scientific Sessions 2022

2) Remote continuous data monitoring and personalized data-driven approach for managing diabetes in a virtual and physical setting, Milena Caccelli\* , Yousef Said, Joena Mojado, Carolyn Palsky, Ali Hashemi & Ihsan Almarzooqi, Diabetes Management, ATTD 2022

3)Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation, Juris J. Meier,Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, Front. Endocrinol., 25 June 2021